市場調查報告書
商品編碼
1439199
全球生化自動診斷市場評估:按組件、儀器類型、應用、最終用戶、地區、機會和預測(2017-2031)Biochemical Auto-Diagnostics Market Assessment, By Component, By Instrument Type, By Application, By End-user, By Region, Opportunities and Forecast, 2017-2031F |
全球生化自動化診斷市場規模預計將從 2023 年的 50.1 億美元增至 2031 年的 78.1 億美元,2024-2031 年預測期間複合年增長率為 5.7%。這個市場主要是由對快速、準確的診斷測試不斷增長的需求所推動的。實驗室程序的自動化、對疾病早期診斷的重視以及生化診斷技術的進步正在成為其他成長動力。慢性病和傳染病導致的疾病負擔迅速增加,對自動化診斷程序的需求顯著增加,進一步擴大了該市場的範圍。老化人口的增加,更容易感染疾病,也增加了對診斷的需求。有關當局對診斷技術擴展的監管支持將進一步推動市場成長。
然而,由於購買和操作自動生化分析儀的成本高昂,實驗室的易擁有性已成為一個問題,這也是製造商面臨的主要挑戰之一。抵制採用新技術和缺乏適當的培訓模組也是公司目前面臨的主要挑戰。
2023年6月,Shenzhen Mindray Bio-Medical Electronics Co., Ltd.(Mindray)推出高通量M1000 Chemistry and Immunoassay Integrated Solution。該解決方案包括BS-2800M Chemistry Analyzer、CL-8000i Chemiluminescence Immunoassay Analyzer和智慧樣品輸送模組。
對快速、準確的診斷測試的需求不斷增長
非傳染性疾病的流行、人口老化以及立即醫療診斷、篩檢和監測的需要等因素推動了對快速、準確的診斷測試的需求不斷增長。由於慢性病盛行率的增加和人口老化,對診斷測試的需求持續增加。隨著即時醫療診斷和調查需求的增加,對先進分析設備和創新技術的需求也會增加。為此,臨床生化分析儀的技術創新不斷進步,使得更早發現疾病並進行更大規模的檢測成為可能。自動化診斷生化分析儀和耗材可以輕鬆滿足不斷增長的診斷需求,進一步擴大市場。製造商正在積極致力於生產快速、精確的生化分析儀的解決方案。
例如,2023 年 5 月,Beckman Coulter推出了DxI 9000 Access Immunoassay Analyzer。DxI 9000 分析儀每小時每平方公尺可進行多達 215 次測試,是佔地面積方面效率最高的免疫分析儀。Beckman Coulter是全球先進診斷解決方案的領先供應商。
測試程序的快速自動化
實驗室程序的快速自動化正在增加對自動化生化分析儀的需求。隨著診斷實驗室變得越來越自動化,先進的設備可以執行數百到數千次測試。因此,對自動化分析設備的需求不斷增加。自動化提供快速、經濟高效且高品質的測試,這對於滿足不斷增加的樣本量和臨床實驗室卓越運作的需求至關重要。幾十年來,自動化也一直是大多數臨床化學工作流程不可或缺的一部分,使實驗室能夠處理更多的測試請求並降低成本。
2023 年 7 月,Beckman Coulter推出了美國 FDA 批准的用於免疫分析診斷的Atellica CI Analyser。Atellica CI Analyser使獨立實驗室和衛星實驗室能夠存取與 Atellica 解決方案相同的試劑、耗材和智慧軟體。該技術設計適合 1.9 平方米的小空間,非常適合空間有限的實驗室。透過實現隨機取樣、微抽吸以及自動安排維護和品質控制,實驗室可以提供更可靠、更及時的結果。
本報告研究和分析了全球生化自動化診斷市場,提供市場規模和預測、市場動態以及主要參與者的現狀和前景。
Global biochemical auto-diagnostics market is projected to witness a CAGR of 5.7% during the forecast period 2024-2031, growing from USD 5.01 billion in 2023 to USD 7.81 billion in 2031. The growing demand for rapid and accurate diagnostic tests primarily drives the biochemical auto-diagnostics market. Automation of laboratory procedures, emphasis on early diagnosis of diseases, and advancements in technologies used for biochemistry diagnostics are acting as other growth-inducing factors. The rapidly growing disease burden of chronic and infectious diseases significantly raises the demand for automated diagnostics procedures, further expanding the scope of this market. The growing geriatric population, which is most prone to catching diseases, increases the demand for diagnostics. Regulatory support from concerned authorities for technology expansion in diagnostics further boosts the market growth.
However, the high cost of purchasing and operating the automated biochemistry analyzer raises affordability issues for laboratories, which is one of the major challenges for the manufacturers. A significant challenge also comes from resistance to adopting new technology and a lack of suitable training modules, although companies are working on this now.
In June 2023, Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (Mindray) launched the high-throughput M1000 Chemistry and Immunoassay Integrated Solution. The solution includes the BS-2800M Chemistry Analyzer, CL-8000i Chemiluminescence Immunoassay Analyzer, and an intelligent sample delivery module.
Growing Demand for Rapid and Accurate Diagnostic Tests
The growing demand for rapid and accurate diagnostic tests is driven by factors such as the rising prevalence of noncommunicable diseases, an aging population, and the need for immediate medical diagnosis, screening, and surveillance. The demand for diagnostic testing continues to rise due to the increasing prevalence of chronic conditions and the aging population. As the need for immediate medical diagnosis and surveillance increases, the demand for advanced analyzers and innovative technologies rises. This has led to technological innovations in clinical chemistry analyzers, enabling early disease detection and testing on a larger scale. The growing demand for diagnostics can be easily catered to through auto-diagnostics biochemistry analyzers and consumables, further expanding the market. Manufacturers are actively involved in producing solutions for rapid and precise biochemistry analyzers.
For instance, in May 2023, Beckman Coulter unveiled the DxI 9000 Access Immunoassay Analyzer. The DxI 9000 Analyzer can perform up to 215 tests per hour per square meter, making it the most productive immunoassay analyzer in terms of footprint. Beckman Coulter is a leading provider of advanced diagnostics solutions across the globe.
Rapid Automation of Laboratory Procedures
The rapid automation of laboratory procedures has increased the demand for automated biochemistry analyzers. As diagnostic laboratories become more automated, sophisticated instruments can complete hundreds to thousands of tests. This has led to an increased demand for automated analyzers. Automation allows for fast, cost-efficient, and high-quality testing, essential to meet the growing sample load and the need for operational excellence in clinical laboratories. Additionally, automation has been an integral part of most clinical chemistry workflows for decades, allowing labs to handle many test requests and reduce costs.
In July 2023, Siemens Healthineers launched a US-FDA-approved Atellica CI Analyser for immunoassay diagnostics. The Atellica CI Analyzer allows standalone and satellite labs to access the same reagents, consumables, and intelligent software as Atellica Solution. This technology has been designed to fit into a small 1.9m2 space, perfect for laboratories with limited space. It allows labs to provide more reliable and timely results by allowing random access sampling, micro-volume aspiration, and automatic scheduling of maintenance and quality control.
Dominance of Fully Automatic Biochemistry Analyzers Segment
Fully automatic biochemistry analyzers are preferred over semi-automatic ones for several reasons. One of the primary advantages is that fully automatic analyzers require little or no manual intervention, reducing the potential for human error. They can also handle a higher throughput of samples, making them more suitable for larger laboratories with high testing volumes. Additionally, fully automatic analyzers offer more automation, from sample addition to result reporting, leading to improved efficiency and streamlined testing processes. Furthermore, the test results of fully automatic analyzers are generally more accurate and convenient than semi-automatic analyzers. Fully automatic analyzers are ideal for high sample volumes and efficient processing, semi-automatic analyzers may be sufficient for smaller laboratories or point-of-care settings with lower sample volumes and can accommodate a slightly longer turnaround time.
In July 2023, Anbio launched a fully automated CLIA analyzer. The Anbio ADL i1910 is an affordable and compact chemiluminescence immunoassay analyzer that provides a comprehensive range of testing options for analytes in human serum, plasma, whole blood, and urine samples. It uses the direct chemiluminescence method to ensure accurate and reliable hormone detection, disease screening, and antigen analysis results.
Hospitals to Lead the End-user Segment
Hospitals use biochemical analyzers for various purposes, including routine check-ups, disease screening, confirmation tests, and diagnosis of different ailments. These analyzers are critical for assessing chemicals in biological samples, analyzing analytes such as proteins, electrolytes, enzymes, and metabolites, and evaluating the performance of organs like the liver, heart, and kidneys. They are also helpful in drug monitoring, detecting drug misuse, and diagnosing infectious diseases. The growing demand for diagnostic testing has led to an increase in the usage of biochemical analyzers, making hospitals one of the primary consumers of these devices. Market players are designing products to cater to the specific requirements of hospitals.
In May 2023, Wondfo launched the Ucare-6000 Automatic Blood Gas Biochemical Analyzer at the 20th China Association of Clinical Laboratory Practice Expo (CACLP). The Ucare-6000 automatic blood gas biochemical analyzer offers accuracy, efficiency, flexibility, and simplified operation. It uses electrochemistry sensing technology, microfluidic technology, and thin-film microelectrode technology. With its sound QC system, it can perform automatic calibration and internal QC to ensure accurate results.
North America to be the Dominating Region
North America is the leading consumer of biochemistry analyzers due to the rising prevalence of chronic diseases, such as diabetes and cardiovascular disorders, which require efficient diagnostic tools to manage and monitor these conditions. The need for rapid and on-site diagnostic solutions is also driving the demand for biochemistry analyzers, and the trend toward miniaturization is contributing to cost-effectiveness. The United States is a significant market for biochemistry analyzers, with high investments in research and development initiatives. The presence of key market players like Beckman Coulter Inc., and Abbott Diagnostics Inc. in the region also contributed to the region's dominance in this market.
Future Market Scenario (2024 - 2031F)
The major drivers of the market include digital transformation for labs, increasing research and development activities across the healthcare industry, and growing expenditure on the diagnostics industry.
The growing affinity of healthcare providers for adopting technology-based solutions for diagnostics is anticipated to increase the demand for the biochemical auto-diagnostics market.
Fully automated biochemical analyzers are preferred over semi-automated biochemical analyzers due to enhanced efficacy and efficiency and are expected to be the dominating segment throughout the assessment period.
Hospitals are anticipated to be the leading end-users for this market due to the growing requirement for rapid diagnostic tests, owing to the high disease burden and growing geriatric population.
Key Players Landscape and Outlook
The key players in the landscape of the biochemical auto-diagnostics market include companies involved in the manufacturing and distribution of biochemistry analyzers and biochemical diagnostic instruments. Some prominent companies in this market are Roche Diagnostics GmbH, Siemens AG, Beckman Coulter Inc., and Abbott Diagnostics. These companies are known for their advanced healthcare technologies and have a significant market presence. The market is expected to witness healthy competition with the integration of new technologies.
In December 2023, Shenzhen Mindray Bio-Medical Electronics Co., Ltd. announced the acquisition of a 75% stake in Germany-based DiaSys Diagnostic Systems GmbH, this acquisition makes DiaSys, a subsidiary of Mindray. The acquisition will expand the IVD offerings of Mindray including the biochemical analyzers.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.